Overview

A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects

Status:
Not yet recruiting

Trial end date:
2023-10-13

Target enrollment:

Participant gender:

Summary

This trial is conducted in China. The aim of the trial is to investigate the influence of IBI362 on pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of warfarin, metformin, warfarin, atorvastatin, digoxin in overweight or obese subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Innovent Biologics (Suzhou) Co. Ltd.

Treatments:

Atorvastatin
Digoxin
Metformin
Warfarin